· ALT-Q5 is a targeted ADC for the treatment of ovarian cancer.
· While the ovarian cancer mortality rate is the highest among all female cancer patients, standard treatment for ovarian cancer for the past 40 years has been only chemotherapy after surgery. This standard treatment has not been successful because approximately 75% of ovarian cancer patients are diagnosed at later stage. Therefore, recurrence rate within 2 years after surgery is 70~80%, and survival rate within 5 years after recurrence stays at 20%. Accordingly, a new and more effective first line treatment for ovarian cancer is badly needed.
· ALT-Q5 is an anti-folate receptor targeting ADC, utilizing NexMab™ ADC technology. It has been reported that folate receptor is over-expressed in 90% ovarian cancer cells. The internalization, one of prerequisite for successful ADC application, is well characterized for folate receptor, and ALT-Q5 exhibited more potent anti-cancer efficacy than combination therapy (Taxol + farletuzumab) in mouse xenograft studies.